Dengue virus and host antibody -a dangerous balancing act
The mosquito-borne dengue virus (DEN) continues to be of intense concern to human health globally. This ongoing status is exacerbated by the lack of a vaccine.
There have been many vaccines attempts, but success has been elusive; for example, recent large-scale trials with attenuated yellow fever virus -DEN chimeric vaccines to stimulate broad immunity against the four DEN serotypes have given largely disappointing results. 1 In the Lancet Infectious Diseases, Osorio and colleagues report 2 on their use of a DEN-2 live attenuated strain (DENVax-2) and the DENVax-2 molecular backbone to express prM and E structural genes for serotypes 1, 3 and 4 to produce a tetravalent DEN vaccine representing each of the four DEN serotypes, with the goal of stimulating broad-based protective immunity. 2 A placebo-controlled, randomised Phase 1 (safety and immunogenicity) study was conducted in a flavivirus naïve, healthy
Colombian population living in a community located 2142 metres above sea level, far from DEN and its transmitting vector (Aedes aegypti).
The vaccine was well tolerated in study participants who received two high or two low doses via the intradermal or subcutaneous inoculation routes. The majority of participants sero-converted to three of the four serotypes (96%), with a significant number (62%) displaying antibody responses to all four DEN serotypes after the second dose. Vaccine viral RNA and infectious virus were detected in some participants.
While encouraging, the spectre hovering over these phase 1 vaccine results is antibody-dependent enhancement (ADE) of DEN in individuals exposed to natural infection, and its association with dengue shock syndrome (DSS) and dengue haemorrhagic fever (DHF Osorio et al. (2) found that sero-conversion rates were quite variable for DEN-3
and DEN-4 after low-and high-dose tetravalent vaccination, which may flag danger for 
